<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32948071</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>18</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Clinical and Molecular Landscape of ALS Patients with <i>SOD1</i> Mutations: Novel Pathogenic Variants and Novel Phenotypes. A Single ALS Center Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6807</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21186807</ELocationID><Abstract><AbstractText>Mutations in the copper zinc superoxide dismutase 1 (<i>SOD1</i>) gene are the second most frequent cause of familial amyotrophic lateral sclerosis (ALS). Nearly 200 mutations of this gene have been described so far. We report all <i>SOD1</i> pathogenic variants identified in patients followed in the single ALS center of Lyon, France, between 2010 and 2020. Twelve patients from 11 unrelated families are described, including two families with the not yet described <i>H81Y</i> and <i>D126N</i> mutations. Splice site mutations were detected in two families. We discuss implications concerning genetic screening of <i>SOD1</i> gene in familial and sporadic ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>Emilien</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3952-9265</Identifier><AffiliationInfo><Affiliation>Centre SLA de Lyon, H&#xf4;pital Neurologique P. Wertheimer, Hospices Civils de Lyon, Universit&#xe9; de Lyon, 59 Boulevard Pinel, 69677 Bron CEDEX, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut NeuroMyoG&#xe8;ne, CNRS UMR5310, INSERM U1217, Facult&#xe9; de M&#xe9;decine Rockefeller, Universit&#xe9; Claude Bernard Lyon I, 8 Avenue Rockefeller, 69373 Lyon CEDEX 08, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegat</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1563-9432</Identifier><AffiliationInfo><Affiliation>Centre SLA de Lyon, H&#xf4;pital Neurologique P. Wertheimer, Hospices Civils de Lyon, Universit&#xe9; de Lyon, 59 Boulevard Pinel, 69677 Bron CEDEX, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svahn</LastName><ForeName>Juliette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre SLA de Lyon, H&#xf4;pital Neurologique P. Wertheimer, Hospices Civils de Lyon, Universit&#xe9; de Lyon, 59 Boulevard Pinel, 69677 Bron CEDEX, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouhour</LastName><ForeName>Fran&#xe7;oise</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre SLA de Lyon, H&#xf4;pital Neurologique P. Wertheimer, Hospices Civils de Lyon, Universit&#xe9; de Lyon, 59 Boulevard Pinel, 69677 Bron CEDEX, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leblanc</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3214-5880</Identifier><AffiliationInfo><Affiliation>Institut NeuroMyoG&#xe8;ne, CNRS UMR5310, INSERM U1217, Facult&#xe9; de M&#xe9;decine Rockefeller, Universit&#xe9; Claude Bernard Lyon I, 8 Avenue Rockefeller, 69373 Lyon CEDEX 08, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millecamps</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut du Cerveau, ICM, Inserm U1127, CNRS UMR7225, Sorbonne Universit&#xe9;, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, 75646 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thobois</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre SLA de Lyon, H&#xf4;pital Neurologique P. Wertheimer, Hospices Civils de Lyon, Universit&#xe9; de Lyon, 59 Boulevard Pinel, 69677 Bron CEDEX, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine Lyon Sud Charles Merieux, Universit&#xe9; Claude Bernard Lyon 1, 69373 Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229, 69675 Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guissart</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Moleculaire, CHU Nimes, Nimes, Motoneuron Disease: Pathophysiology and Therapy, INM, University Montpellier, 30029 N&#xee;mes CEDEX 9, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumbroso</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Moleculaire, CHU Nimes, Nimes, Motoneuron Disease: Pathophysiology and Therapy, INM, University Montpellier, 30029 N&#xee;mes CEDEX 9, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouzat</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Moleculaire, CHU Nimes, Nimes, Motoneuron Disease: Pathophysiology and Therapy, INM, University Montpellier, 30029 N&#xee;mes CEDEX 9, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="Y">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">copper zinc superoxide dismutase 1</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>19</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32948071</ArticleId><ArticleId IdType="pmc">PMC7554847</ArticleId><ArticleId IdType="doi">10.3390/ijms21186807</ArticleId><ArticleId IdType="pii">ijms21186807</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., Van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S., Goizet C., Soulages A., Vallat J.M., Masson G.L. Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.Y., Zhou Z.R., Che C.H., Liu C.Y., He R.L., Huang H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M., Nilsson P., Ala-Hurula V., Ker&#xe4;nen M.L., Tarvainen I., Haltia T., Nilsson L., Binzer M., Forsgren L., Marklund S.L. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat. Genet. 1995;10:61&#x2013;66. doi: 10.1038/ng0595-61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0595-61</ArticleId><ArticleId IdType="pubmed">7647793</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander M.D., Traynor B.J., Miller N., Corr B., Frost E., McQuaid S., Brett F.M., Green A., Hardiman O. &#x201c;True&#x201d; sporadic ALS associated with a novel SOD-1 mutation. Ann. Neurol. 2002;52:680&#x2013;683. doi: 10.1002/ana.10369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10369</ArticleId><ArticleId IdType="pubmed">12402272</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumen S.C., Inzelberg R., Nisipeanu P., Carasso R.L., Oved D., Aizenstein O., Drory V.E., Bergstrom C., Andersen P.M. Aggressive familial ALS with unusual brain MRI and a SOD1 gene mutation. Amyotroph. Lateral Scler. 2010;11:228&#x2013;231. doi: 10.3109/17482960902878376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902878376</ArticleId><ArticleId IdType="pubmed">19363716</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G., Corcia P., Lenglet T., Stojkovic T., Leguern E., Cazeneuve C., Pradat P.F. Motor neuron disease of very long disease duration or Charcot-Marie-Tooth disease? A novel phenotype related to the SOD1 p.E22G variant. Rev. Neurol. (Paris) 2017;173:671&#x2013;673. doi: 10.1016/j.neurol.2017.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.05.008</ArticleId><ArticleId IdType="pubmed">28579206</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Salachas F., Cazeneuve C., Gordon P., Bricka B., Camuzat A., Guillot-No&#xeb;l L., Russaouen O., Bruneteau G., Pradat P.F., et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: Genotype-phenotype correlations. J. Med. Genet. 2010;47:554&#x2013;560. doi: 10.1136/jmg.2010.077180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2010.077180</ArticleId><ArticleId IdType="pubmed">20577002</ArticleId></ArticleIdList></Reference><Reference><Citation>Abati E., Bresolin N., Comi G., Corti S. Silence superoxide dismutase 1 (SOD1): A promising therapeutic target for amyotrophic lateral sclerosis (ALS) Expert Opin. Ther. Targets. 2020;24:295&#x2013;310. doi: 10.1080/14728222.2020.1738390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1738390</ArticleId><ArticleId IdType="pubmed">32125907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali T., Self W., Liu J., Siddique T., Wang L.H., Bird T.D., Ratti E., Atassi N., Boylan K.B., Glass J.D., et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J. Neurol. Neurosurg. Psychiatry. 2017;88:99&#x2013;105. doi: 10.1136/jnnp-2016-313521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313521</ArticleId><ArticleId IdType="pmc">PMC5136332</ArticleId><ArticleId IdType="pubmed">27261500</ArticleId></ArticleIdList></Reference><Reference><Citation>Brotherton T., Polak M., Kelly C., Birve A., Andersen P., Marklund S.L., Glass J.D. A novel ALS SOD1 C6S mutation with implications for aggregation related toxicity and genetic counseling. Amyotroph. Lateral Scler. 2011;12:215&#x2013;219. doi: 10.3109/17482968.2010.531279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.531279</ArticleId><ArticleId IdType="pubmed">21073275</ArticleId></ArticleIdList></Reference><Reference><Citation>Keckarevi&#x107; D., Stevi&#x107; Z., Keckarevi&#x107;-Markovi&#x107; M., Kecmanovi&#x107; M., Romac S. A novel P66S mutation in exon 3 of the SOD1 gene with early onset and rapid progression. Amyotroph. Lateral Scler. 2012;13:237&#x2013;240. doi: 10.3109/17482968.2011.627588.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.627588</ArticleId><ArticleId IdType="pubmed">22214314</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapp P.C., Rosen D.R., Hosler B.A., Esteban J., McKenna-Yasek D., O&#x2019;Regan J.P., Horvitz H.R., Brown R.H., Jr. Identification of three novel mutations in the gene for Cu/Zn superoxide dismutase in patients with familial amyotrophic lateral sclerosis. Neuromuscul. Disord. 1995;5:353&#x2013;357. doi: 10.1016/0960-8966(95)00007-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0960-8966(95)00007-A</ArticleId><ArticleId IdType="pubmed">7496169</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromicho M., Pinto S., Gisca E., Pronto-Laborinho A.C., Andersen P.M., De Carvalho M. Frequency of C9orf72 hexanucleotide repeat expansion and SOD1 mutations in Portuguese patients with amyotrophic lateral sclerosis. Neurobiol. Aging. 2018;70:325.e7&#x2013;325.e15. doi: 10.1016/j.neurobiolaging.2018.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.05.009</ArticleId><ArticleId IdType="pubmed">29861044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kab S., Moisan F., Preux P.M., Marin B., Elbaz A. Nationwide incidence of motor neuron disease using the French health insurance information system database. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017;18:426&#x2013;433. doi: 10.1080/21678421.2017.1306566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1306566</ArticleId><ArticleId IdType="pubmed">28387141</ArticleId></ArticleIdList></Reference><Reference><Citation>Luigetti M., Cianfoni A., Conte A., Sabatelli M. Gadolinium enhancement of the lumbar leptomeninges and roots in a case of ALS. Amyotroph. Lateral Scler. 2010;11:412&#x2013;413. doi: 10.3109/17482960903234728.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903234728</ArticleId><ArticleId IdType="pubmed">19929746</ArticleId></ArticleIdList></Reference><Reference><Citation>Young N.P., Laughlin R.S., Sorenson E.J. Gadolinium enhancement of the lumbar roots in a case of ALS. Amyotroph. Lateral Scler. 2010;11:207&#x2013;209. doi: 10.3109/17482960802642161.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802642161</ArticleId><ArticleId IdType="pubmed">19177251</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman J.S., Crow J.P., Estevez A.G. Response to &#x2018;Toxicity of ALS-linked SOD1 mutants&#x2019;. Williamson, T.L.; Corson, L.B.; Huang, L.; Burlingame, A.; Liu, J.; Bruijn, L.I.; Cleveland, D.W. Science. 2000;288:399a.</Citation><ArticleIdList><ArticleId IdType="pubmed">10798964</ArticleId></ArticleIdList></Reference><Reference><Citation>Enayat Z.E., Orrell R.W., Claus A., Ludolph A., Bachus R., Brockm&#xfc;ller J., Ray-Chaudhuri K., Radunovic A., Shaw C., Wilkinson J., et al. Two novel mutations in the gene for copper zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis. Hum. Mol. Genet. 1995;4:1239&#x2013;1240. doi: 10.1093/hmg/4.7.1239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/4.7.1239</ArticleId><ArticleId IdType="pubmed">8528216</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Lasseigne B.N., Petrovski S., Sapp P.C., Dion P.A., Leblond C.S., Couthouis J., Lu Y.F., Wang Q., Krueger B.J., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi K., Mochizuki Y., Koide R., Kawata A., Homma T., Shimizu T., Komori T., Isozaki E. A Japanese familial ALS patient with autonomic failure and a p.Cys146Arg mutation in the gene for SOD1 (SOD1) Neuropathology. 2016;36:551&#x2013;555. doi: 10.1111/neup.12303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12303</ArticleId><ArticleId IdType="pubmed">27090969</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimson B.S., Thompson H.S. Raeder&#x2019;s syndrome. A clinical review. Surv. Ophthalmol. 1980;24:199&#x2013;210. doi: 10.1016/0039-6257(80)90041-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0039-6257(80)90041-7</ArticleId><ArticleId IdType="pubmed">6244681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P., Hanna M.G., Fisher E.M., Sidle K. An unusual presentation for SOD1-ALS: Isolated facial diplegia. Muscle Nerve. 2013;48:994&#x2013;995. doi: 10.1002/mus.23958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23958</ArticleId><ArticleId IdType="pubmed">23873540</ArticleId></ArticleIdList></Reference><Reference><Citation>Salameh J.S., Atassi N., David W.S. SOD1 (A4V)-mediated ALS presenting with lower motor neuron facial diplegia and unilateral vocal cord paralysis. Muscle Nerve. 2009;40:880&#x2013;882. doi: 10.1002/mus.21321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21321</ArticleId><ArticleId IdType="pubmed">19618436</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopate G., Baloh R.H., Al-Lozi M.T., Miller T.M., Fernandes Filho J.A., Ni O., Leston A., Florence J., Schierbecker J., Allred P. Familial ALS with extreme phenotypic variability due to the I113T SOD1 mutation. Amyotroph. Lateral Scler. 2010;11:232&#x2013;236. doi: 10.3109/17482960902898069.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902898069</ArticleId><ArticleId IdType="pubmed">20184521</ArticleId></ArticleIdList></Reference><Reference><Citation>Origone P., Caponnetto C., Mantero V., Cichero E., Fossa P., Geroldi A., Verdiani S., Bellone E., Mancardi G., Mandich P. Fast course ALS presenting with vocal cord paralysis: Clinical features, bioinformatic and modelling analysis of the novel SOD1 Gly147Ser mutation. Amyotroph. Lateral Scler. 2012;13:144&#x2013;148. doi: 10.3109/17482968.2011.614254.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.614254</ArticleId><ArticleId IdType="pubmed">21929355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawata A., Kato S., Hayashi H., Hirai S. Prominent sensory and autonomic disturbance in familial amyotrophic lateral sclerosis with a Gly93Ser mutation in the SOD1 gene. J. Neurol. Sci. 1977;153:82&#x2013;85. doi: 10.1016/S0022-510X(97)00176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00176-7</ArticleId><ArticleId IdType="pubmed">9455983</ArticleId></ArticleIdList></Reference><Reference><Citation>Hineno A., Nakamura A., Shimojima Y., Yoshida K., Oyanagai K., Ikeda S. Distinctive clinicopathological features of 2 large families with amyotrophic lateral sclerosis having L106V mutation in SOD1 gene. J. Neurol. Sci. 2012;319:63&#x2013;74. doi: 10.1016/j.jns.2012.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2012.05.014</ArticleId><ArticleId IdType="pubmed">22647583</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T., Kawata A., Kato S., Hayashi M., Takamoto K., Hayashi H., Hirai S., Yamaguchi S., Komori T., Oda M. Autonomic failure in ALS with a novel SOD1 gene mutation. Neurology. 2000;54:1534&#x2013;1537. doi: 10.1212/WNL.54.7.1534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.54.7.1534</ArticleId><ArticleId IdType="pubmed">10751275</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. ACMG Laboratory Quality Assurance Committee. Genet. Med. 2015;17:405&#x2013;424. doi: 10.1038/gim.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Den Dunnen J.T., Dalgleish R., Maglott D.R., Hart R.K., Greenblatt M.S., McGowan-Jordan J., Roux A.F., Smith T., Antonarakis S.E., Taschner P.E. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum. Mutat. 2016;37:564&#x2013;569. doi: 10.1002/humu.22981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22981</ArticleId><ArticleId IdType="pubmed">26931183</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>